TABLE 2.
Current clinical trials on Nanogel based cancer vaccine candidates.
| Nanogel Based Vaccine Candidate | Adjuvant/Additive | Cancer Type | Clinical Phase | Reference |
|---|---|---|---|---|
| CHP-HER2 | Lung, breast, pancreatic, nasal cavity, pelvis cancers | I | Kitano et al. (2006) | |
| GM-CSF/OK-432 | Breast, ovarian, non-small cell lung cancer | 1 | Kageyama et al. (2008) | |
| CHP-NY-ESO-1 | Esophageal, prostate, malignant melanoma | 1 | Kawabata et al. (2007), Tsuji et al. (2008), Uenaka et al. (2007), Wada et al. (2008) | |
| Esophageal cancer | 1 | Kageyama et al. (2013), Kawada et al. (2012) | ||
| OK-432 | Advanced esophageal cancer | I | Aoki et al. (2009) | |
| MIS416, anti-PD-I | Urothelial, prostate, synovial sarcoma, malignant solid tumors | I | Ishihara et al. (2020) | |
| Poly ICLC, Anti-PD-1 | Esophageal | 1 | Ishikawa et al. (2021) | |
| CHP-NY-ESO-1 plus CHP-HER2 | OK-432 | Esophageal cancer | 1 | Aoki et al. (2009) |
| CHP-MAGE-A4 | OK-432 | Esophageal, lung and gastric cancers | 1 | Saito et al. (2014) |
| OK-432 | Colon, esophageal, papilla of Vater, breast, pancreatic cancers | I &II | Kyogoku et al. (2016) | |
| OK-432 | Colon, rectal, breast, bile duct, gall bladder, pancreatic or mesothelioma | I & II | Kengo Miyauchi1 et al. (2016) | |
| OK-432 | Colorectal, breast, bile duct, gall bladder, pancreatic or mesothelioma | I &II | Wada et al. (2018) | |
| OK-432 | Esophageal carcinoma, head/neck, ovarian, duodenal cancers | I | Ueda et al. (2018) |